Dupont Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Dupont Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,469	Closed	-$158K	–	1733
2022 Q2	$158K	Sell	11,469 -16,810	-59%	-$269K	0.01%	1045
2022 Q1	$460K	Sell	28,279 -2,501	-8%	-$39.2K	0.02%	809
2021 Q4	$501K	Buy	30,780 +9,846	+47%	+$166K	0.02%	778
2021 Q3	$311K	Sell	20,934 -2,960	-12%	-$47.4K	0.01%	1059
2021 Q2	$477K	Hold	23,894	–	–	0.01%	1026
2021 Q1	$551K	Buy	23,894 +16,211	+211%	+$452K	0.01%	869
2020 Q4	$190K	Sell	7,683 -574	-7%	-$19K	﹤0.01%	1144
2020 Q3	$342K	Buy	8,257 +2,588	+46%	+$119K	0.01%	928
2020 Q2	$272K	Buy	5,669 +2,165	+62%	+$167K	0.01%	1009
2020 Q1	$221K	Buy	+3,504	New	+$315K	0.01%	983

Other funds holding ICPT

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dupont Capital Management's ICPT Position: Q3 2022 in Review

Dupont Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2022, closing a stake of 11,469 shares — an estimated $158K sold.

Dupont Capital Management first reported a position in ICPT in Q1 2020 and held it in 10 quarters. The position peaked at $551K in Q1 2021. 156 funds tracked by Wall St. Rank hold ICPT as of Q3 2022.

Dupont Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Dupont Capital Management sold 11,469 Intercept Pharmaceuticals, Inc. shares in Q3 2022, an estimated $158K.
Dupont Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2020 and held it in 10 quarters.
Dupont Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $551K in Q1 2021.
156 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2022.

Based on Dupont Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.